ResMed Guides 62%-63% Gross Margin for FY2026, Plans $175M Q4 Buyback, Closes Noctrix Acquisition in June

Sleep apnea device maker ResMed has released its financial outlook, projecting gross margins between 62% and 63% for fiscal 2026. The company also announced plans to execute over $175 million in share repurchases in the fourth quarter and expects to complete its approximately $340 million acquisition of neuromodulation technology firm Noctrix Health by June 1. These moves underscore ResMed's dual strategy of capital allocation and business expansion to solidify its leadership in sleep-disordered breathing treatment.

Gross Margin Outlook: Cost Control and Product Mix Optimization

During its latest earnings call, ResMed's management set a gross margin target of 62% to 63% for fiscal 2026. The guidance reflects expectations around raw material cost fluctuations, supply chain efficiency gains, and a higher share of value-added products. Despite ongoing global inflationary pressures, ResMed aims to maintain healthy margins through automated production upgrades and supplier diversification. Analysts note that this range is slightly above the industry average, highlighting the company's pricing power and operational efficiency.

Share Buyback Plan: Boosting Shareholder Confidence

ResMed announced it will allocate more than $175 million to share repurchases in the fourth quarter. Such a move is typically seen as a signal that management believes the stock is undervalued or has strong confidence in future growth. Based on the company's historical buyback pace, this amount represents over 60% of its quarterly free cash flow. The repurchase program will be executed in the open market, with timing and size adjusted flexibly based on market conditions. Market observers believe that amid valuation pressure in the medical device sector, ResMed's buyback could help stabilize its stock price and boost earnings per share.

Noctrix Acquisition: Entering the Neuromodulation Arena

ResMed plans to acquire Noctrix Health for approximately $340 million, with the transaction expected to close on June 1. Noctrix specializes in developing neuromodulation therapies for obstructive sleep apnea (OSA), with its core product improving airway patency through hypoglossal nerve stimulation. This acquisition will help ResMed expand beyond traditional CPAP (continuous positive airway pressure) devices into broader neuromodulation technologies. Industry analysis shows the global OSA treatment market is growing at roughly 8% annually, with non-CPAP therapies gaining share. ResMed's move positions it to capitalize on technological shifts and reduce reliance on a single product line.

Financial Impact and Integration Risks

While the acquisition outlook is positive, ResMed faces integration challenges. Noctrix is still in its early commercialization stage, and its products have yet to achieve significant profitability. ResMed plans to leverage its global sales network and clinical resources to accelerate Noctrix product penetration, but this may pressure R&D expenses and operating costs in the near term. The $340 million purchase price represents about 1.5% of ResMed's current market capitalization. The company says it will fund the deal through existing cash reserves and debt financing, without affecting its planned buyback program.

Competitive Landscape and Regulatory Environment

ResMed's main competitors in the sleep apnea space include Philips Respironics and Fisher & Paykel Healthcare. Philips' ventilator recall has led to market share losses, creating an opportunity for ResMed. However, the FDA's medical device approval standards are becoming increasingly stringent, and Noctrix's neuromodulation devices will require additional post-market regulatory clearances. ResMed stated in its announcement that it has reached preliminary consensus with regulators on product compliance, but final approval timelines remain uncertain.

Market Reaction and Analyst Views

Following the earnings release, ResMed's shares saw modest gains in after-hours trading. Several investment banks maintained "buy" ratings, with target prices offering roughly 15% upside from current levels. Institutions generally believe the gross margin guidance and buyback provide near-term support, while the Noctrix acquisition opens long-term growth avenues. However, some analysts caution that if macroeconomic conditions worsen and patients delay non-urgent medical spending, ResMed's revenue growth could slow.

Risk Disclaimer

The above content is for reference only and does not constitute investment advice. The medical device industry is subject to regulatory policies, technological changes, and competitive dynamics. ResMed's financial targets and acquisition plans may not be realized as expected. Investors should make decisions based on their own risk tolerance.